title: [Analysis of the cytosolic content of the pS2 protein in breast cancer].
abstract: OBJECTIVE
  To analyze pS2 cytosolic levels in breast carcinomas and their correlation with different clinical characteristics of the patients and their tumours.
  
  
  METHODS
  Cytosolic pS2 levels were measured by radioimmunometric assay in tumours from 168 breast cancer patients.
  
  
  RESULTS
  The pS2 values ranged from 0 to 251 ng/mg protein (mean SD: 21.8 38.1; median: 7.9 ng/mg protein). These protein levels were significantly (p < 0.05) higher in premenopausal patients (27.6 45.2) than in postmenopausal patients (19.5 33.8). Intratumour pS2 levels were also significantly (p < 0.05) correlated with histologic grade of the tumours, and were higher in well diferentiated tumours (grade I: 28.8 42.8) than in moderately differentiated tumours (grade II: 19.7 35.6) and than in poorly differentiated tumours (grade III: 18.9 37.3). Similarly, significant differences in pS2 content were found between positive estrogen receptor (ER) tumours and ER-negative tumours (29.1 46.5 vs 11.3 15.9, respectively; p<0.0001), as well as between positive progesterone receptor (PR) tumours and PR-negative tumours (29.1 49.8 vs 15.3 21.5, respectively; p < 0.05).
  
  
  CONCLUSIONS
  The results suggest that pS2 may be a useful prognostic marker in breast cancer, and may also be useful to identify patients who are likely to benefit from hormone therapy.
authors.affiliation: Servicio de Cirugía General, Hospital de Jove, Gijón. Oviedo. Spain.
authors.forename: F
authors.initials: F
authors.lastname: Tamargo
authors.forename: F
authors.initials: F
authors.lastname: Vizoso
authors.forename: M L
authors.initials: ML
authors.lastname: Lamelas
authors.forename: A
authors.initials: A
authors.lastname: Rodil
authors.forename: P
authors.initials: P
authors.lastname: Vérez
authors.forename: P
authors.initials: P
authors.lastname: Raigoso
authors.forename: M
authors.initials: M
authors.lastname: Mulero
authors.forename: J
authors.initials: J
authors.lastname: Vázquez
authors.forename: C
authors.initials: C
authors.lastname: Roiz
authors.forename: M T
authors.initials: MT
authors.lastname: Allende
mesh_terms: D000328:Adult; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000737:chemistry* / Q000473:pathology; D002454:Cell Differentiation; D003600:Cytosol / Q000737:chemistry*; D004967:Estrogens; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008593:Menopause; D009363:Neoplasm Proteins / Q000032:analysis*; D009376:Neoplasms, Hormone-Dependent / Q000737:chemistry / Q000473:pathology; D011374:Progesterone; D011379:Prognosis; D011506:Proteins / Q000032:analysis*; D011863:Radioimmunoassay; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D000071163:Trefoil Factor-1; D025521:Tumor Suppressor Proteins
chemical_list: D014408:Biomarkers, Tumor; D004967:Estrogens; D009363:Neoplasm Proteins; D011506:Proteins; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C051838:TFF1 protein, human; D000071163:Trefoil Factor-1; D025521:Tumor Suppressor Proteins; D011374:Progesterone